|
FR2709309B1
(en)
*
|
1993-08-25 |
1995-11-10 |
Centre Nat Rech Scient |
Cellular compositions, preparation and therapeutic uses.
|
|
JPH11514209A
(en)
*
|
1995-04-20 |
1999-12-07 |
カイロン コーポレイション |
Highly efficient ex vivo transduction of hematopoietic stem cells with recombinant retrovirus preparations
|
|
AU702266B2
(en)
*
|
1995-08-25 |
1999-02-18 |
Regents Of The University Of California, The |
Chimeric antiviral agents which incorporate Rev binding nucleic acids
|
|
US6316210B1
(en)
|
1995-12-20 |
2001-11-13 |
Subsidiary No. 3, Inc. |
Genetic suppressor elements against human immunodeficiency virus
|
|
US6426412B1
(en)
*
|
1995-12-20 |
2002-07-30 |
Subsidiary No. 3, Inc. |
Nucleic acids encoding human immunodeficiency virus type 1 genetic suppressor elements
|
|
FR2746109B1
(en)
|
1996-03-12 |
1998-04-17 |
Rhone Poulenc Rorer Sa |
ENVIRONMENT FOR THE CONSERVATION OF BIOLOGICAL MATERIAL
|
|
EP2298900A1
(en)
|
1996-09-17 |
2011-03-23 |
Novartis Vaccines and Diagnostics, Inc. |
Compositions and methods for treating intracellular diseases
|
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
|
US6071743A
(en)
|
1997-06-02 |
2000-06-06 |
Subsidiary No. 3, Inc. |
Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
|
|
US6537972B1
(en)
|
1997-06-02 |
2003-03-25 |
Subsidiary No. 3., Inc. |
Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
|
|
US6001558A
(en)
*
|
1997-06-25 |
1999-12-14 |
Ortho Clinical Diagnostics, Inc. |
Amplification and detection of HIV-1 and/or HIV 2
|
|
DE69838584T2
(en)
|
1997-08-04 |
2008-06-26 |
Cell Genesys, Inc., Foster City |
ENHANCERS OF HUMAN GLANDULAR CALLIQUE, VECTORS CONTAINING HIM, AND METHODS FOR ITS USE
|
|
JP2002516061A
(en)
|
1997-10-14 |
2002-06-04 |
ダーウィン モレキュラー コーポレイション |
Mutants of thymidine kinase and fusion proteins having thymidine kinase activity and guanylate kinase activity
|
|
CA2671261A1
(en)
|
1997-11-06 |
1999-05-20 |
Novartis Vaccines And Diagnostics S.R.L. |
Neisserial antigens
|
|
EP1047784B2
(en)
|
1998-01-14 |
2015-03-18 |
Novartis Vaccines and Diagnostics S.r.l. |
Neissera meningitidis antigens
|
|
WO1999053031A2
(en)
*
|
1998-04-08 |
1999-10-21 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Process for producing cell clone libraries
|
|
EP2261338A3
(en)
|
1998-05-01 |
2012-01-04 |
Novartis Vaccines and Diagnostics, Inc. |
Neisseria meningitidis antigens and compositions
|
|
WO1999057265A1
(en)
*
|
1998-05-04 |
1999-11-11 |
Julianna Lisziewicz |
Chimeric decoy rnas having synergistic anti-hiv activity
|
|
US6613506B1
(en)
|
2000-11-28 |
2003-09-02 |
Subsidiary No. 3, Inc. |
Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
|
|
ATE386804T1
(en)
|
1998-10-15 |
2008-03-15 |
Novartis Vaccines & Diagnostic |
GENES WITH ALTERED EXPRESSION IN METASTATIC BREAST OR COLON CANCER CELLS
|
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
|
ATE481487T1
(en)
|
1998-11-27 |
2010-10-15 |
Ucb Sa |
COMPOSITIONS AND METHODS FOR INCREASE BONE MINERALIZATION
|
|
EP1961813B1
(en)
|
1998-12-16 |
2011-08-10 |
Novartis Vaccines and Diagnostics, Inc. |
Human cyclin-dependent kinase (hPNQALRE)
|
|
US7063850B1
(en)
|
1998-12-22 |
2006-06-20 |
University Of Tennessee Research Foundation |
Protective antigen of group A Streptococci
|
|
AU2221600A
(en)
|
1998-12-31 |
2000-07-31 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
|
US7625859B1
(en)
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
|
US6911429B2
(en)
|
1999-04-01 |
2005-06-28 |
Transition Therapeutics Inc. |
Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
|
|
US6864235B1
(en)
|
1999-04-01 |
2005-03-08 |
Eva A. Turley |
Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
|
|
CA2365901A1
(en)
*
|
1999-04-14 |
2000-10-19 |
Musc Foundation For Research Development |
Tissue-specific and pathogen-specific toxic agents and ribozymes
|
|
WO2000066741A2
(en)
|
1999-04-30 |
2000-11-09 |
Chiron S.P.A. |
Conserved neisserial antigens
|
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
|
JP2004508801A
(en)
|
1999-10-29 |
2004-03-25 |
カイロン ソチエタ ア レスポンサビリタ リミタータ |
Neisseria antigenic peptide
|
|
EP2163626A1
(en)
|
1999-11-18 |
2010-03-17 |
Novartis Vaccines and Diagnostics, Inc. |
Human FGF-21 gene and gene expression products
|
|
PT2289545T
(en)
|
2000-01-17 |
2016-09-06 |
Glaxosmithkline Biologicals Sa |
Supplemented omv vaccine against meningococcus
|
|
WO2001057245A2
(en)
*
|
2000-02-04 |
2001-08-09 |
K.U.Leuven Research & Development |
Hiv-1 resistance assay
|
|
EP1854476A3
(en)
|
2000-02-09 |
2008-05-07 |
Bas Medical, Inc. |
Use of relaxin to treat diseases related to vasoconstriction
|
|
WO2001066595A2
(en)
|
2000-03-08 |
2001-09-13 |
Chiron Corporation |
Human fgf-23 gene and gene expression products
|
|
EP1950297A2
(en)
|
2000-05-31 |
2008-07-30 |
Novartis Vaccines and Diagnostics, Inc. |
Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
|
|
WO2003057926A1
(en)
|
2002-01-08 |
2003-07-17 |
Chiron Corporation |
Gene products differentially expressed in cancerous breast cells and their methods of use
|
|
US7700359B2
(en)
|
2000-06-02 |
2010-04-20 |
Novartis Vaccines And Diagnostics, Inc. |
Gene products differentially expressed in cancerous cells
|
|
ES2305087T3
(en)
|
2000-06-15 |
2008-11-01 |
Novartis Vaccines And Diagnostics, Inc. |
POLINUCLEOTIDOS RELATED TO CANCER DE COLON.
|
|
CA2881568C
(en)
|
2000-10-27 |
2019-09-24 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acids and proteins from streptococcus groups a & b
|
|
JP2004535765A
(en)
|
2000-12-07 |
2004-12-02 |
カイロン コーポレイション |
Endogenous retrovirus up-regulated in prostate cancer
|
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
|
AU2002258728A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
|
WO2002081639A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
|
WO2002081641A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
|
EP1967525B1
(en)
|
2001-05-08 |
2012-11-14 |
Darwin Molecular Corporation |
A method for regulating immune function in primates using the foxp3 protein
|
|
EP2280074A3
(en)
|
2001-07-05 |
2011-06-22 |
Novartis Vaccines and Diagnostics, Inc. |
Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
|
|
EP1411770A4
(en)
|
2001-07-05 |
2006-05-10 |
Chiron Corp |
POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF
|
|
US7270827B2
(en)
|
2001-10-26 |
2007-09-18 |
University Of Tennessee Research Foundation |
Multivalent streptococcal vaccine compositions and methods for use
|
|
WO2003039491A2
(en)
|
2001-11-09 |
2003-05-15 |
Georgetown University |
Novel isoforms of vascular endothelial cell growth inhibitor
|
|
RU2331435C2
(en)
|
2001-12-12 |
2008-08-20 |
Чирон Срл. |
Immunisation against chlamydia trachomatis
|
|
AU2003218162B2
(en)
|
2002-03-15 |
2009-10-29 |
The Curators Of The University Of Missouri |
Mutants of the P4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
|
|
EP2093233A1
(en)
|
2002-03-21 |
2009-08-26 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
|
US7138512B2
(en)
|
2002-04-10 |
2006-11-21 |
Georgetown University |
Gene SHINC-2 and diagnostic and therapeutic uses thereof
|
|
US8518694B2
(en)
|
2002-06-13 |
2013-08-27 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
|
|
WO2005000194A2
(en)
|
2002-10-08 |
2005-01-06 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
|
|
UA80447C2
(en)
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
|
ZA200502612B
(en)
|
2002-10-08 |
2007-07-25 |
Rinat Neuroscience Corp |
Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
|
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
|
DK2270048T3
(en)
|
2002-12-24 |
2016-01-18 |
Rinat Neuroscience Corp |
Anti-NGF antibodies and methods for their use
|
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
|
US20040170982A1
(en)
|
2003-02-14 |
2004-09-02 |
Morris David W. |
Novel therapeutic targets in cancer
|
|
JP2007524362A
(en)
|
2003-02-14 |
2007-08-30 |
サイグレス ディスカバリー， インコーポレイテッド |
Therapeutic GPCR targets in cancer
|
|
US7767387B2
(en)
|
2003-06-13 |
2010-08-03 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
|
BRPI0407375A
(en)
|
2003-02-19 |
2006-02-07 |
Rinat Neuroscience Corp |
Methods for treating pain by administering a neural growth factor antagonist and a nsaid and compositions containing same
|
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
|
EP2353389B1
(en)
|
2003-04-21 |
2015-11-04 |
Epeius Biotechnologies Corporation |
Compositions for treating disorders
|
|
US20070178066A1
(en)
|
2003-04-21 |
2007-08-02 |
Hall Frederick L |
Pathotropic targeted gene delivery system for cancer and other disorders
|
|
WO2005020928A2
(en)
|
2003-08-29 |
2005-03-10 |
The Regents Of The University Of California |
Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
|
|
AP2006003670A0
(en)
|
2003-12-23 |
2006-06-30 |
Rinat Neuroscience Corp |
Agonist anti-TRKC antibodies and methods using same
|
|
JP4792390B2
(en)
|
2004-03-29 |
2011-10-12 |
株式会社ガルファーマ |
Novel galectin-9 variant protein and use thereof
|
|
EP3372614B1
(en)
|
2004-04-07 |
2022-06-08 |
Rinat Neuroscience Corp. |
Methods for treating bone cancer pain by administering a nerve growth factor antagonist
|
|
AU2005327194B2
(en)
|
2004-07-09 |
2010-09-09 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Soluble forms of Hendra and Nipah virus G glycoprotein
|
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
|
MX2007000998A
(en)
|
2004-07-30 |
2007-07-11 |
Rinat Neuroscience Corp |
Antibodies directed against amyloid-beta peptide and methods using same.
|
|
JP2008530245A
(en)
|
2005-02-18 |
2008-08-07 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド |
Antigens from uropathogenic strains
|
|
CA2604844A1
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics, Inc. |
Cancer-related genes
|
|
EP1865981A2
(en)
|
2005-04-07 |
2007-12-19 |
Chiron Corporation |
Cacna1e in cancer diagnosis, detection and treatment
|
|
EP1907425B1
(en)
|
2005-07-22 |
2014-01-08 |
Y's Therapeutics Co., Ltd. |
Anti-cd26 antibodies and methods of use thereof
|
|
EP3069731A1
(en)
|
2005-11-14 |
2016-09-21 |
Labrys Biologics Inc. |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
|
JP2009525319A
(en)
|
2006-02-02 |
2009-07-09 |
ライナット ニューロサイエンス コーポレイション |
Method of treating obesity by administering a trkB antagonist
|
|
CA2643732C
(en)
|
2006-02-27 |
2012-08-21 |
The Regents Of The University Of California |
Oxysterol compounds and the hedgehog pathway
|
|
CA2652703C
(en)
|
2006-06-07 |
2018-08-28 |
Bioalliance C.V. |
Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
|
|
PT2054431E
(en)
|
2006-06-09 |
2011-11-03 |
Novartis Ag |
Conformers of bacterial adhesins
|
|
EP2586790A3
(en)
|
2006-08-16 |
2013-08-14 |
Novartis AG |
Immunogens from uropathogenic Escherichia coli
|
|
EP2139447A2
(en)
|
2007-03-20 |
2010-01-06 |
Harold Brem |
Gm-csf cosmeceutical compositions and methods of use thereof
|
|
US20100261640A1
(en)
|
2007-04-10 |
2010-10-14 |
Branco Luis M |
Soluble and membrane anchored forms of lassa virus subunit proteins
|
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
|
CN101951915A
(en)
|
2007-12-03 |
2011-01-19 |
加利福尼亚大学董事会 |
Oxsterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and WNT signaling
|
|
BRPI0822049B1
(en)
|
2007-12-17 |
2021-11-16 |
Pfizer Limited |
PHARMACEUTICAL COMPOSITION COMPRISING ANTI-NGF ANTAGONIST ANTIBODY, KIT AND USE OF AN ANTINGF ANTIBODY
|
|
HUE026846T2
(en)
|
2007-12-18 |
2016-08-29 |
Bioalliance Cv |
Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
|
|
EP3023502A1
(en)
|
2008-04-10 |
2016-05-25 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting egfr mutations in cancer
|
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
|
TWI516501B
(en)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Pcsk9 antagonists
|
|
CN102224254A
(en)
|
2008-09-23 |
2011-10-19 |
哈佛大学校长及研究员协会 |
Sirt4 and uses thereof
|
|
WO2010080985A1
(en)
|
2009-01-08 |
2010-07-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for induced brown fat differentiation
|
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
|
US8568732B2
(en)
|
2009-03-06 |
2013-10-29 |
Novartis Ag |
Chlamydia antigens
|
|
WO2010118243A2
(en)
|
2009-04-08 |
2010-10-14 |
Genentech, Inc. |
Use of il-27 antagonists to treat lupus
|
|
EP3263128A3
(en)
|
2009-04-14 |
2018-01-24 |
GlaxoSmithKline Biologicals S.A. |
Compositions for immunising against staphylococcus aureus
|
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
|
AU2010272243A1
(en)
|
2009-07-16 |
2012-03-08 |
Novartis Ag |
Detoxified Escherichia coli immunogens
|
|
US8563261B2
(en)
|
2009-09-28 |
2013-10-22 |
The Trustees Of The University Of Pennsylvania |
Method of diagnosing and treating interstitial cystitis
|
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
|
JP2013517772A
(en)
|
2010-01-21 |
2013-05-20 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
A situation-specific gene screening platform to aid gene discovery and target confirmation
|
|
AR080291A1
(en)
|
2010-02-24 |
2012-03-28 |
Rinat Neuroscience Corp |
ANTI-BODIES ANTAGONISTS ANTI RECEIVER OF IL-7 AND PROCEDURES
|
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
|
JP5932670B2
(en)
|
2010-03-11 |
2016-06-08 |
ライナット ニューロサイエンス コーポレイション |
Antibody with pH-dependent antigen binding
|
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
|
JP2013533286A
(en)
|
2010-07-30 |
2013-08-22 |
セントルイス ユニバーシティ |
How to treat pain
|
|
US9539427B2
(en)
|
2010-11-08 |
2017-01-10 |
The Johns Hopkins University |
Methods for improving heart function
|
|
WO2012075243A2
(en)
|
2010-12-01 |
2012-06-07 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for targeting sites of neovascular growth
|
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
|
US20130071375A1
(en)
|
2011-08-22 |
2013-03-21 |
Saint Louis University |
Compositions and methods for treating inflammation
|
|
WO2013028527A1
(en)
|
2011-08-23 |
2013-02-28 |
Indiana University Research And Technology Corporation |
Compositions and methods for treating cancer
|
|
CA2848368C
(en)
|
2011-09-13 |
2023-02-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for brown fat induction and activity using fndc5
|
|
US10378060B2
(en)
|
2011-10-14 |
2019-08-13 |
Dana-Farber Cancer Institute, Inc. |
ZNF365/ZFP365 biomarker predictive of anti-cancer response
|
|
TWI495644B
(en)
|
2011-11-11 |
2015-08-11 |
Rinat Neuroscience Corp |
Specific antibody of trophic cell surface antigen (Trop-2) and their use
|
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
|
US9249224B2
(en)
|
2011-12-22 |
2016-02-02 |
Rinat Neuroscience Corp. |
Human growth hormone receptor antagonist antibodies and methods of use thereof
|
|
RU2737765C2
(en)
|
2012-05-04 |
2020-12-02 |
Пфайзер Инк. |
Prostate-associated antigens and immunotherapeutic regimens based on vaccines
|
|
CA2872751A1
(en)
|
2012-05-07 |
2013-11-14 |
The Regents Of The University Of California |
Oxysterol analogue oxy133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis
|
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
|
CA2890483A1
(en)
|
2012-11-09 |
2014-05-15 |
Robert ARCH |
Platelet-derived growth factor b specific antibodies and compositions and uses thereof
|
|
AU2014236208B2
(en)
|
2013-03-14 |
2018-07-19 |
Genvivo, Inc. |
Thymidine kinase diagnostic assay for gene therapy applications
|
|
AU2014240045A1
(en)
|
2013-03-15 |
2015-09-10 |
Dyax Corp. |
Anti-plasma kallikrein antibodies
|
|
JP2016517888A
(en)
|
2013-05-02 |
2016-06-20 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Oxysterol bone targeting drug for osteoselective bone formation
|
|
WO2014181229A2
(en)
|
2013-05-07 |
2014-11-13 |
Rinat Neuroscience Corp. |
Anti-glucagon receptor antibodies and methods of use thereof
|
|
WO2015006641A2
(en)
|
2013-07-12 |
2015-01-15 |
Georgia State University Research Foundation, Inc. |
Methods and compositions for interference with dna polymerase and dna synthesis
|
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
|
CA2919790C
(en)
|
2013-08-02 |
2018-06-19 |
Pfizer Inc. |
Anti-cxcr4 antibodies and antibody-drug conjugates
|
|
US9683998B2
(en)
|
2013-11-13 |
2017-06-20 |
Pfizer Inc. |
Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
|
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
|
AU2015230933B2
(en)
|
2014-03-21 |
2020-08-13 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
|
US10428158B2
(en)
|
2014-03-27 |
2019-10-01 |
Dyax Corp. |
Compositions and methods for treatment of diabetic macular edema
|
|
EP3134546A4
(en)
|
2014-04-24 |
2017-12-06 |
Dana-Farber Cancer Institute, Inc. |
Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
|
|
WO2015168474A1
(en)
|
2014-04-30 |
2015-11-05 |
President And Fellows Of Harvard College |
Fusion proteins for treating cancer and related methods
|
|
ES2913205T3
(en)
|
2014-05-13 |
2022-06-01 |
Bioatla Inc |
Conditionally active biological proteins
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
DK4074735T3
(en)
|
2014-08-28 |
2025-07-14 |
Bioatla Inc |
CONDITIONALLY ACTIVE CHIMERIC ANTIGEN RECEPTORS FOR MODIFIED T-CELLS
|
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
WO2016036916A1
(en)
|
2014-09-03 |
2016-03-10 |
Bioatla, Llc |
Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
|
|
CA2972714A1
(en)
|
2014-09-09 |
2016-03-17 |
Unum Therapeutics |
Chimeric receptors and uses thereof in immune therapy
|
|
CA2963091A1
(en)
|
2014-10-06 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
|
WO2016057651A1
(en)
|
2014-10-09 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Multiple-variable il-2 dose regimen for treating immune disorders
|
|
TWI595006B
(en)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
Anti-PD-1 antibodies and methods of using same
|
|
CN107405399B
(en)
|
2015-01-02 |
2022-02-08 |
武田药品工业株式会社 |
Bispecific antibodies against plasma kallikrein and factor XII
|
|
WO2016144673A1
(en)
|
2015-03-06 |
2016-09-15 |
Dana-Farber Cancer Institute, Inc. |
Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
|
|
US9758575B2
(en)
|
2015-04-06 |
2017-09-12 |
Yung Shin Pharmaceutical Industrial Co. Ltd. |
Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
|
|
TWI703159B
(en)
|
2015-04-13 |
2020-09-01 |
美商輝瑞股份有限公司 |
Bcma-specific therapeutic antibodies and their uses
|
|
WO2017015334A1
(en)
|
2015-07-21 |
2017-01-26 |
Saint Louis University |
Compositions and methods for diagnosing and treating endometriosis-related infertility
|
|
AU2016297018B9
(en)
|
2015-07-21 |
2022-12-01 |
Takeda Pharmaceutical Company Limited |
A monoclonal antibody inhibitor of factor XIIa
|
|
US11066481B2
(en)
|
2015-07-23 |
2021-07-20 |
The Regents Of The University Of California |
Antibodies to coagulation factor XIa and uses thereof
|
|
KR102438650B1
(en)
|
2015-08-19 |
2022-08-31 |
화이자 인코포레이티드 |
Tissue factor pathway inhibitor antibodies and uses thereof
|
|
HRP20211081T1
(en)
|
2015-09-15 |
2021-10-15 |
Scholar Rock, Inc. |
ANTI-PRO / LATENT MYOSTATIN ANTIBODIES AND THEIR USES
|
|
AU2016337525B2
(en)
|
2015-10-16 |
2022-01-20 |
The Trustees Of Columbia University In The City Of New York |
Compositions and methods for inhibition of lineage specific antigens
|
|
US11207393B2
(en)
|
2015-10-16 |
2021-12-28 |
President And Fellows Of Harvard College |
Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
|
|
CN115636880A
(en)
|
2015-10-23 |
2023-01-24 |
辉瑞有限公司 |
anti-IL-2 antibodies and compositions and uses thereof
|
|
WO2017075037A1
(en)
|
2015-10-27 |
2017-05-04 |
Scholar Rock, Inc. |
Primed growth factors and uses thereof
|
|
AU2016343978A1
(en)
|
2015-10-29 |
2018-05-17 |
Dana-Farber Cancer Institute, Inc. |
Methods for identification, assessment, prevention, and treatment of metabolic disorders using PM20D1 and N-lipidated amino acids
|
|
CN106699889A
(en)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技（上海）有限公司 |
PD-1 resisting antibody and treatment application thereof
|
|
KR20250057128A
(en)
|
2015-12-30 |
2025-04-28 |
코디악 사이언시스 인코포레이티드 |
Antibodies and conjugates thereof
|
|
CN109219618B
(en)
|
2016-01-21 |
2022-08-09 |
辉瑞大药厂 |
Monospecific and bispecific antibodies against epidermal growth factor receptor variants III and CD3 and uses thereof
|
|
WO2017165412A2
(en)
|
2016-03-21 |
2017-09-28 |
Dana-Farber Cancer Institute, Inc. |
T-cell exhaustion state-specific gene expression regulators and uses thereof
|
|
PL3455261T3
(en)
|
2016-05-13 |
2022-12-12 |
Bioatla, Inc. |
ANTI-ROR2 ANTIBODY, ANTIBODY FRAGMENTS, THEIR IMMUNOCJUGATES AND THEIR APPLICATIONS
|
|
AU2017290805B2
(en)
|
2016-07-01 |
2023-11-16 |
Research Development Foundation |
Elimination of proliferating cells from stem cell-derived grafts
|
|
ES3033182T3
(en)
|
2016-09-20 |
2025-07-31 |
Dana Farber Cancer Inst Inc |
Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
|
|
US20180119141A1
(en)
|
2016-10-28 |
2018-05-03 |
Massachusetts Institute Of Technology |
Crispr/cas global regulator screening platform
|
|
US20190345501A1
(en)
|
2017-02-07 |
2019-11-14 |
Massachusetts Institute Of Technology |
Methods and compositions for rna-guided genetic circuits
|
|
CA3054885A1
(en)
|
2017-03-03 |
2018-09-07 |
Rinat Neuroscience Corp. |
Anti-gitr antibodies and methods of use thereof
|
|
WO2018167621A1
(en)
|
2017-03-16 |
2018-09-20 |
Pfizer Inc. |
Tyrosine prototrophy
|
|
CA3059938A1
(en)
|
2017-04-14 |
2018-10-18 |
Kodiak Sciences Inc. |
Complement factor d antagonist antibodies and conjugates thereof
|
|
EP3615570A4
(en)
|
2017-04-25 |
2021-02-24 |
LBL Biotechnology Inc. |
Use of il-20 antagonists for treating eye diseases
|
|
MY201312A
(en)
|
2017-06-02 |
2024-02-16 |
Pfizer |
Antibodies specific for flt3 and their uses
|
|
US11820822B2
(en)
|
2017-06-06 |
2023-11-21 |
Dana-Farber Cancer Institute, Inc. |
Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
|
|
GB202209539D0
(en)
|
2017-06-13 |
2022-08-10 |
Bostongene Corp |
Systems and methods for identifying cancer treatments from normalized biomarker scores
|
|
WO2019016784A1
(en)
|
2017-07-21 |
2019-01-24 |
Universidade De Coimbra |
Anti-nucleolin antibody
|
|
CN111093715A
(en)
|
2017-09-18 |
2020-05-01 |
儿童医院医疗中心 |
Strong insulators and their use in gene delivery
|
|
EP3692370A2
(en)
|
2017-10-04 |
2020-08-12 |
OPKO Pharmaceuticals, LLC |
Articles and methods directed to personalized therapy of cancer
|
|
EP3688011A4
(en)
|
2017-10-25 |
2021-11-24 |
The Administrators Of The Tulane Educational Fund |
PEPTIDIAL COMPOSITIONS AND METHODS FOR USING SUCH COMPOSITIONS
|
|
CA3080120C
(en)
|
2017-10-27 |
2023-11-21 |
New York University |
Anti-galectin-9 antibodies and uses thereof
|
|
PE20210708A1
(en)
|
2018-02-01 |
2021-04-16 |
Pfizer |
ANTIBODIES SPECIFIC TO CD70 AND THEIR USES
|
|
CN112020518A
(en)
|
2018-02-01 |
2020-12-01 |
辉瑞公司 |
Chimeric Antigen Receptor Targeting CD70
|
|
WO2019168897A2
(en)
|
2018-02-28 |
2019-09-06 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
|
|
AU2019228381B2
(en)
|
2018-02-28 |
2021-12-16 |
Pfizer Inc. |
IL-15 variants and uses thereof
|
|
EP3758737A4
(en)
|
2018-03-02 |
2022-10-12 |
Kodiak Sciences Inc. |
ANTI-IL-6 ANTIBODIES AND RELATED FUSION CONSTRUCTS AND CONJUGATES
|
|
JP7429192B2
(en)
|
2018-04-06 |
2024-02-07 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
KIR3DL3 as HHLA2 receptor, anti-HHLA2 antibody and its use
|
|
KR102602329B1
(en)
|
2018-05-23 |
2023-11-16 |
화이자 인코포레이티드 |
Antibodies specific for CD3 and their uses
|
|
MX2020012607A
(en)
|
2018-05-23 |
2021-01-29 |
Pfizer |
Antibodies specific for gucy2c and uses thereof.
|
|
AU2019299439C1
(en)
|
2018-07-03 |
2025-06-26 |
Sotio Biotech, Inc. |
Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
|
|
JP7456638B2
(en)
|
2018-08-14 |
2024-03-27 |
ソティオ，リミティド ライアビリティ カンパニー |
Chimeric antigen receptor polypeptides combined with transmetabolic molecules that modulate the Krebs cycle and their therapeutic uses
|
|
CA3110837A1
(en)
|
2018-08-28 |
2020-03-05 |
Vor Biopharma Inc. |
Genetically engineered hematopoietic stem cells and uses thereof
|
|
JP7603580B2
(en)
|
2018-10-15 |
2024-12-20 |
エリクシロン・イミュノセラピューティクス・（ホンコン）・リミテッド |
Antibodies to granulocyte-macrophage colony-stimulating factor and uses thereof
|
|
WO2020132190A1
(en)
|
2018-12-21 |
2020-06-25 |
Multitude Inc. |
Antibodies specific to muc18
|
|
US12084500B2
(en)
|
2019-01-23 |
2024-09-10 |
New York University |
Antibodies specific to delta 1 chain of T cell receptor
|
|
EP3962529A4
(en)
|
2019-04-30 |
2023-11-01 |
Dana-Farber Cancer Institute, Inc. |
METHOD FOR CANCER TREATMENT USING ANTI-CX3CR1 AND IMMUNE CHECKPOINT BLOCKING REAGENTS COMBINATIONS
|
|
US12205675B2
(en)
|
2019-07-03 |
2025-01-21 |
Bostongene Corporation |
Techniques for bias correction in sequence data
|
|
WO2021071830A1
(en)
|
2019-10-07 |
2021-04-15 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
WO2021072244A1
(en)
|
2019-10-11 |
2021-04-15 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-tn antibodies and uses thereof
|
|
US20230067811A1
(en)
|
2020-01-24 |
2023-03-02 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
|
EP4093513A4
(en)
|
2020-01-24 |
2024-05-08 |
Dana-Farber Cancer Institute, Inc. |
USE OF BIOMARKERS TO IMPROVE IMMUNOTHERAPY
|
|
WO2021205325A1
(en)
|
2020-04-08 |
2021-10-14 |
Pfizer Inc. |
Anti-gucy2c antibodies and uses thereof
|
|
WO2021224850A1
(en)
|
2020-05-06 |
2021-11-11 |
Crispr Therapeutics Ag |
Mask peptides and masked anti-ptk7 antibodies comprising such
|
|
US20230235007A1
(en)
|
2020-06-15 |
2023-07-27 |
Ming-Che Shih |
Humanized ace2-fc fusion protein for treatment and prevention of sars-cov-2 infection
|
|
MX2023000662A
(en)
|
2020-07-17 |
2023-02-27 |
Pfizer |
THERAPEUTIC ANTIBODIES AND THEIR USES.
|
|
CA3190227A1
(en)
|
2020-07-30 |
2022-02-03 |
Pfizer Inc. |
Cells having gene duplications and uses thereof
|
|
EP4343004A3
(en)
|
2020-10-19 |
2024-09-11 |
Dana-Farber Cancer Institute, Inc. |
Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
|
|
WO2022104104A2
(en)
|
2020-11-13 |
2022-05-19 |
Dana-Farber Cancer Institute, Inc. |
Personalized fusion cell vaccines
|
|
US12254961B2
(en)
|
2020-12-04 |
2025-03-18 |
Bostongene Corporation |
Hierarchical machine learning techniques for identifying molecular categories from expression data
|
|
WO2022159793A2
(en)
|
2021-01-25 |
2022-07-28 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for identifying neuroendocrine prostate cancer
|
|
JP2024517745A
(en)
|
2021-04-29 |
2024-04-23 |
ボストンジーン コーポレイション |
Machine learning techniques for predicting tumor cell expression in complex tumor tissues
|
|
US20240280561A1
(en)
|
2021-06-08 |
2024-08-22 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
|
CA3227875A1
(en)
|
2021-08-02 |
2023-02-09 |
Pfizer Inc. |
Improved expression vectors and uses thereof
|
|
WO2023049933A1
(en)
|
2021-09-27 |
2023-03-30 |
Sotio Biotech Inc. |
Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
|
|
AU2022388928A1
(en)
|
2021-11-16 |
2024-05-16 |
Sotio Biotech Inc. |
Treatment of myxoid/round cell liposarcoma patients
|
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
|
CA3249858A1
(en)
|
2022-01-31 |
2023-08-03 |
Bostongene Corporation |
Machine learning techniques for cytometry
|
|
WO2023148598A1
(en)
|
2022-02-02 |
2023-08-10 |
Pfizer Inc. |
Cysteine prototrophy
|
|
EP4479080A1
(en)
|
2022-02-16 |
2024-12-25 |
Dana-Farber Cancer Institute, Inc. |
Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof
|
|
US20240029884A1
(en)
|
2022-07-15 |
2024-01-25 |
Bostongene Corporation |
Techniques for detecting homologous recombination deficiency (hrd)
|
|
WO2024040207A1
(en)
|
2022-08-19 |
2024-02-22 |
Sotio Biotech Inc. |
Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
|
|
WO2024040208A1
(en)
|
2022-08-19 |
2024-02-22 |
Sotio Biotech Inc. |
Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
|
|
WO2024215987A1
(en)
|
2023-04-14 |
2024-10-17 |
Sotio Biotech Inc. |
IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
|
|
EP4694916A1
(en)
|
2023-04-14 |
2026-02-18 |
SOTIO Biotech Inc. |
Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists
|
|
WO2025030010A1
(en)
|
2023-08-01 |
2025-02-06 |
Vor Biopharma Inc. |
Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof
|
|
WO2025034542A1
(en)
|
2023-08-04 |
2025-02-13 |
Cornell University |
Gene signature panel predicting cancer response to immune checkpoint blockade and radiation therapy
|
|
US20260120879A1
(en)
|
2023-10-31 |
2026-04-30 |
Bostongene Corporation |
Machine learning technique for identifying ici responders and non-responders
|
|
US20250253011A1
(en)
|
2024-02-02 |
2025-08-07 |
Seven Bridges Genomics Inc. |
Techniques for improved tumor mutational burden (tmb) determination using a population-specific genomic reference
|